KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Quest Diagnostics (DGX) over the last 16 years, with Dec 2024 value amounting to $549.0 million.

  • Quest Diagnostics' Cash & Equivalents fell 43.46% to $432.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $432.0 million, marking a year-over-year decrease of 43.46%. This contributed to the annual value of $549.0 million for FY2024, which is 19.97% down from last year.
  • Per Quest Diagnostics' latest filing, its Cash & Equivalents stood at $549.0 million for FY2024, which was down 19.97% from $686.0 million recorded in FY2023.
  • Over the past 5 years, Quest Diagnostics' Cash & Equivalents peaked at $1.2 billion during FY2020, and registered a low of $315.0 million during FY2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $549.0 million (2024), whereas its average is $516.7 million.
  • Per our database at Business Quant, Quest Diagnostics' Cash & Equivalents plummeted by 63.88% in 2022 and then skyrocketed by 117.78% in 2023.
  • Quest Diagnostics' Cash & Equivalents (Yearly) stood at $1.2 billion in 2020, then dropped by 24.70% to $872.0 million in 2021, then slumped by 63.88% to $315.0 million in 2022, then surged by 117.78% to $686.0 million in 2023, then decreased by 19.97% to $549.0 million in 2024.